NeuroOne Medical Technologies (Nasdaq:NMTC) announced that it appointed Christopher R. Volker as its chief operating officer (COO).
Volker joins the Eden Prairie, Minnesota-based neurotech company from Abbott. He previously served as VP and GM of international at Cardiovascular Systems (CSI), which Abbott acquired earlier this year.
“Chris’ appointment further strengthens our executive leadership team and deepens our capabilities as we build for future commercial growth and expansion into other clinical applications,” said NeuroOne CEO Dave Rosa. “We are excited to benefit from his broad experience in business development, commercial expansion, finance and health economics, and reimbursement.”
NeuroOne commercially launched its Evo sEEG electrode line in the U.S. earlier this year. The electrodes provide up to 30 days of recording, monitoring and stimulation of electrical signals at the subsurface level of the brain.
The company is also targeting an FDA clearance this year for its first therapeutic device, the OneRF ablation system, which uses already-implanted sEEG electrodes to record brain activity and enable the ablation of nervous tissue.
More about NeuroOne’s new COO
At CSI, Volker had direct responsibility for international commercial expansion, including therapy development and driving sales growth. Before CSI, Volker held executive leadership roles at St. Jude Medical, which Abbott also acquired. At St. Jude, he led corporate development, global strategic market research and health economics & reimbursement strategy.
“I am thrilled to join the talented NeuroOne team and look forward to helping build broad awareness of the company’s exciting unique electrode platform, with better tools for physicians to treat patients suffering from a variety of debilitating neurological conditions,” Volker said.
NeuroOne also announced that its board approved an equity award under its 2021 inducement plan. In connection with entering into employment, Volker received an option to purchase 324,560 NeuroOne common stock shares. The award has an exercise price of $1.32 per share.
